Eagle Point Credit Co (ECC): Management’s unaudited estimate of the range of the net asset value per common share as of October 31, 2026 was between $3.73 and $3.83

Eagle Point Credit Co (ECC) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. Management’s unaudited estimate of the range of the net asset value per common share as of October 31, 2026 was between $3.73 and $3.83. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, Eagle Point Credit Company has duly cau

Original reporting
Published Nov 10, 2026, 12:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 12:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ECC
Neutral
medium confidence
Mentioned
$ECC
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ECCNeutralLow
01

Why it matters

The filing supplies fresh valuation data that may influence investor sentiment and short‑term price action.

02

Market read

A routine NAV update with modest trading relevance for ECC and peers in the credit fund space.

03

What to watch

Potential impact of upcoming portfolio changes or credit market conditions not disclosed in the filing.

Relevance 5/10Novelty 6/10Timing: pre‑market today

Background

Eagle Point Credit Co filed an 8‑K item 8.01 reporting its unaudited net asset value per share estimate for the end of October 2026.

Company-level read

Ticker impact

$ECCNeutralMedium confidence
Context

SEC 8‑K reports management's unaudited NAV estimate of $3.73‑$3.83 per share as of Oct 31 2026.

Expected impact

likely modest pressure or support depending on market reaction to the NAV range

Evidence & confidence

NAV updates are routine but provide fresh valuation data; impact is limited without a significant deviation from prior estimates.

Market effects

Provides a data point for the BDC/closed‑end credit sector valuation.

Limited to U.S. listed credit funds and investors tracking NAV disclosures.

Minimal; does not affect broader market trends.

Counterpoint

If the NAV estimate is higher than market expectations, the stock could rally despite typical modest moves.

Key entities

  • Eagle Point Credit Co

    A publicly traded closed‑end credit fund (ticker ECC).

Related articles

$ECCMed

Eagle Point Q3 2026 slides: private credit shift drives diversification

Eagle Point Credit Company (ECC) reported Q3 2026 results, with net investment income rising to $0.31 per share. The company is shifting toward private credit, now 38% of its portfolio. NAV declined 8% to $4.17 per share. ECC trades at $2.295, up 7.75% from the previous close. Management declared monthly distributions of $0.06 per share for early 2027. The company's AUM stands at $14 billion.

$BRFHMed

Barfresh Manufacturing Recovery Drives Margins – Quarterly Update Report

Barfresh Manufacturing (BRFH) reported 3Q26 revenue of $5.8M, up 37% y/y, with gross margin rebounding to 20.9% from negative 3.2% q/q. Core margins reached 34%, and adjusted EBITDA neared breakeven. The company added 50 Ohio school districts and reactivated a major Florida district. 2026 revenue guidance was revised to $20M-$22M, with Defiance facility commissioning targeted for early to mid-2027. BRFH trades at a 75% discount to peers, offering potential rerating as growth accelerates.

$PYXSHighAI 9/10

Pyxis reports updated phase 1 data for cancer drug candidate

Pyxis Oncology (PYXS) reported updated Phase 1 data for micvotabart pelidotin, showing a 39% response rate in 33 patients with recurrent/metastatic head and neck cancer. The study reported a median progression-free survival of 6.7 months and a 94% disease control rate. Pyxis plans to initiate a Phase 3 trial in mid-2027 and expects to release more mature overall survival data in the first half of 2027.

$PYXSMedAI 8/10

Pyxis Oncology (PYXS) Reports 39% Confirmed MICVO Response Rate

Pyxis Oncology (PYXS) reported updated Phase 1 data for MICVO, showing a 39% confirmed response rate, 9.2-month median response duration, and 6.7-month median PFS in 33 patients. The company plans to start a global Phase 3 trial in mid-2027. The data is not yet confirmatory, and further results are expected in early 2027.